Edition:
United States

Nice Ltd (NICE.TA)

NICE.TA on Tel Aviv Stock Exchange

30,910.00ILa
14 Dec 2017
Change (% chg)

-640.00 (-2.03%)
Prev Close
31,550.00
Open
31,570.00
Day's High
31,570.00
Day's Low
30,750.00
Volume
256,327
Avg. Vol
74,227
52-wk High
31,570.00
52-wk Low
23,930.00

Chart for

About

NICE Ltd., formerly NICE-Systems Ltd., is a global enterprise software provider. The Company's segments include Customer Interactions Solutions, and Financial Crime and Compliance Solutions. The Customer Interactions Solutions segment provides data driven insights that enable businesses to deliver personalized experience to... (more)

Overall

Beta: 0.97
Market Cap(Mil.): ₪18,743.63
Shares Outstanding(Mil.): 60.76
Dividend: 58.64
Yield (%): 0.76

Financials

  Industry Sector
P/E (TTM): -- 33.26 16.04
EPS (TTM): -- -- --
ROI: -- 15.59 34.69
ROE: -- 18.46 15.46

Israel's Nice tops Q3 estimates, tweaks 2017 profit forecast

JERUSALEM, Nov 2 Israeli software provider Nice narrowed the range of its 2017 earnings estimate after topping third-quarter forecasts boosted by higher revenue in its omni-channel, cloud, analytics and artificial intelligence businesses.

Nov 02 2017

BRIEF-Nice Ltd reports Q3 earnings per share of $0.42

* ‍Q3 2017 total revenues increased 36.1% to $322.8 million compared to $237.2 million for Q3 of 2016​

Nov 02 2017

UK's NICE gives Roche drug green light for bladder cancer

LONDON Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

Oct 31 2017

UK's NICE gives Roche drug green light for bladder cancer

LONDON, Nov 1 Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

Oct 31 2017

BRIEF-Migdal Insurance & Financial Holdings reports 4.95 pct passive stake ​ in Nice as of Oct 26

* Migdal Insurance & Financial Holdings Ltd reports 4.95 percent passive stake ​ in Nice Ltd as of Oct 26 - SEC filing Source text: (http://bit.ly/2lxaLhu) Further company coverage:

Oct 31 2017

UK finds Roche bladder cancer drug too costly for routine use

LONDON Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

Aug 02 2017

UK finds Roche bladder cancer drug too costly for routine use

LONDON, Aug 2 Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

Aug 02 2017

Earnings vs. Estimates